{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:06:07Z","timestamp":1761764767039},"publisher-location":"Chichester, UK","reference-count":42,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd004434.pub3","type":"reference-entry","created":{"date-parts":[[2006,7,18]],"date-time":"2006-07-18T16:38:24Z","timestamp":1153240704000},"source":"Crossref","is-referenced-by-count":22,"title":["Endothelin receptor antagonists for pulmonary arterial hypertension"],"prefix":"10.1002","author":[{"given":"Chao","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junmin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,19]]},"reference":[{"key":"10.1002\/14651858.CD004434.pub3-BIB1|cit1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Amercian Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004434.pub3-BIB2|cit2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Amercian Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004434.pub3-BIB3|cit3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Amercian Journal of Respiratory and Critical Care Medicine"},{"issue":"9288","key":"10.1002\/14651858.CD004434.pub3-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD004434.pub3-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0735-1097(03)00121-9","article-title":"Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension","volume":"41","author":"Gali\u00e8","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub3-BIB6|cit6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"The European Respiratory Journal"},{"issue":"12","key":"10.1002\/14651858.CD004434.pub3-BIB7|cit7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"The New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD004434.pub3-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study","volume":"171","author":"Wilkins","year":"2005","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub3-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1378\/chest.121.6.1860","article-title":"Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study","volume":"121","author":"Barst","year":"2002","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub3-BIB10|cit10","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0009-9236(03)00005-5","article-title":"Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension","volume":"73","author":"Barst","year":"2003","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub3-BIB11|cit11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.vph.2005.03.003","article-title":"The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect","volume":"43","author":"Frost","year":"2005","journal-title":"Vascular Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD004434.pub3-BIB12|cit12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijcard.2004.08.025","article-title":"Safety and tolerability of bosentan in adults with Eisenmenger physiology","volume":"98","author":"Gatzoulis","year":"2005","journal-title":"International Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub3-BIB13|cit13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.03.00008003","article-title":"Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids","volume":"22","author":"Hoeper","year":"2003","journal-title":"European Respiratory Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004434.pub3-BIB14|cit14","first-page":"1646","article-title":"Long-term, open-label experience with an endothelin receptor antagonist, Bosentan, in patients with severe heart failure","volume":"100","author":"Krum","year":"1999","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004434.pub3-BIB15|cit15","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1097\/01.fjc.0000166207.74178.d0","article-title":"STRIDE 1: Effects of the selective ETA receptor antagonist sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials","volume":"44","author":"Langleben","year":"2004","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub3-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1378\/chest.126.4.1377","article-title":"Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study","volume":"126","author":"Langleben","year":"2004","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub3-BIB17|cit17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09031936.05.00054804","article-title":"Survival with first-line bosentan in patients with primary pulmonary hypertension","volume":"25","author":"McLaughlin","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD004434.pub3-BIB18|cit18","series-title":"American College of Cardiology 51 st Annual Scientific Session, Atlanta, GA","article-title":"Effects of the endothelin receptor antagonist bosentan on the morbidity and mortality in patients with chronic heart failure: results of the Enable 1 and 2 trial program","author":"Packer","year":"2002"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub3-BIB19|cit19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1253\/circj.69.131","article-title":"Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension","volume":"69","author":"Sasayama","year":"2005","journal-title":"Circulation Journal"},{"key":"10.1002\/14651858.CD004434.pub3-BIB20|cit20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0091270004270833","article-title":"Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects","volume":"45","author":"Giersbergen","year":"2005","journal-title":"Journal of clinical pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub3-BIB21|cit21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/01.CIR.102.4.411","article-title":"Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension","volume":"102","author":"Williamson","year":"2000","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD004434.pub3-BIB22|cit22","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Annals of internal medicine"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub3-BIB23|cit23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group","volume":"334","author":"Barst","year":"1996","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004434.pub3-BIB24|cit24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub3-BIB25|cit25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1476-5381.1995.tb15868.x","article-title":"Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors","volume":"115","author":"Filep","year":"1995","journal-title":"British Journal of Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub3-BIB26|cit26","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.70.4.580","article-title":"Primary pulmonary hypertension: natural history and importance of thrombosis","volume":"70","author":"Fuster","year":"1984","journal-title":"Circulation"},{"issue":"24","key":"10.1002\/14651858.CD004434.pub3-BIB27|cit27","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.ehj.2004.09.014","article-title":"Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology","volume":"25","author":"Galie","year":"2004","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD004434.pub3-BIB28|cit28","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"1-3","key":"10.1002\/14651858.CD004434.pub3-BIB29|cit29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0014-2999(96)00125-2","article-title":"Effects of Ro 47-0203 on endothelin-1 and sarafotoxin S6c-induced contractions of human bronchus and guinea-pig trachea","volume":"304","author":"Gater","year":"1996","journal-title":"European Journal of Pharmacology"},{"key":"10.1002\/14651858.CD004434.pub3-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"17","key":"10.1002\/14651858.CD004434.pub3-BIB31|cit31","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/01.CIR.101.17.2066","article-title":"Improvement in exercise capacity with nitric oxide inhalation in patients with precapillary pulmonary hypertension","volume":"101","author":"Hasuda","year":"2000","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004434.pub3-BIB32|cit32","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/cvr\/27.12.2125","article-title":"Endothelin receptors in cultured adult rat cardiac fibroblasts","volume":"27","author":"Katwa","year":"1993","journal-title":"Cardiovascular Research"},{"issue":"4","key":"10.1002\/14651858.CD004434.pub3-BIB33|cit33","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/019021400404555","article-title":"Pulmonary vascular remodeling distal to pulmonary artery ligation is accompanied by upregulation of endothelin receptors and nitric oxide synthase","volume":"26","author":"Kim","year":"2000","journal-title":"Experimental Lung Research"},{"issue":"3","key":"10.1002\/14651858.CD004434.pub3-BIB34|cit34","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1006\/bbrc.1995.2560","article-title":"Endothelin induced collagen remodeling in experimental pulmonary hypertension","volume":"215","author":"Mansoor","year":"1995","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1002\/14651858.CD004434.pub3-BIB35|cit35","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/ajrccm.161.2.9906015","article-title":"Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing","volume":"161","author":"Miyamoto","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub3-BIB36|cit36","article-title":"Prostacyclin for pulmonary hypertension","author":"Paramothayan","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004434.pub3-BIB37|cit37","first-page":"342","article-title":"The case for treatment of selected patients with primary pulmonary hypertension","volume":"134","author":"Reeves","year":"1986","journal-title":"The American Review of Respiratory Disease"},{"issue":"2","key":"10.1002\/14651858.CD004434.pub3-BIB38|cit38","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD004434.pub3-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1378\/chest.120.5.1562","article-title":"Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension","volume":"120","author":"Rubens","year":"2001","journal-title":"Chest"},{"key":"10.1002\/14651858.CD004434.pub3-BIB40|cit40","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1378\/chest.104.1.236","article-title":"ACCP consensus statement: primary pulmonary hypertension","volume":"104","author":"Rubin","year":"1987","journal-title":"Chest"},{"key":"10.1002\/14651858.CD004434.pub3-BIB41|cit41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1183\/09031936.98.12020265","article-title":"Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension","volume":"12","author":"Sitbon","year":"1998","journal-title":"The European Respiratory Journal"},{"key":"10.1002\/14651858.CD004434.pub3-BIB42|cit42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1165\/ajrcmb.25.1.4331","article-title":"Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling","volume":"25","author":"Wort","year":"2001","journal-title":"American Journal of Respiratory Cell and Molecular Biology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD004434.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:35:08Z","timestamp":1628530508000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD004434.pub3"}},"subtitle":[],"editor":[{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2006,7,19]]},"references-count":42,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004434.pub3","relation":{},"subject":[],"published":{"date-parts":[[2006,7,19]]}}}